Abstract:Bladder cancer (BCa) is one of the most common malignancies with more than 500,000 new cases diagnosed each year. Intravesical instillations of Bacillus Calmette-Guérin (BCG) is the gold-standard treatment for non-muscle invasive BCa (NMIBC) patients despite significant side effects and high rates of refractory disease and/or recurrence. Indeed, treatment failure occurs in ~40% of cases emphasizing the urgent need to evaluate alternative and/or complementary new therapies including immunotherapies. Recently, the use of immune checkpoint inhibitor (ICI) anti-PD-1 therapy has been approved for the treatment of BCG-unresponsive NMIBC patients. Here, we investigated whether targeting PD-1 or CTLA-4 can boost anti-tumor immunity in the orthotopic murine MB49 BCa model. To this purpose, 2.5 × 105 luciferase-expressing MB49 cells (MB49-Luc) have been instilled into the preconditioned bladder of female C57Bl/6 mice by intra-urethral catheterization. In vivo tumor growth has been monitored three times a week using the IVIS spectrum in vivo imaging system. All the inoculated mice showed a luciferase signal at day 3 post-bladder tumor inoculation, demonstrating 100% of tumor uptake. Based on the in vivo bioluminescence, a randomization has been performed before ICI treatment consisting of anti-CTLA-4 (10 μg/mouse; q3dx4, intraperitoneal) or anti-PD-1 (100 μg/mouse, q3dx4, intraperitoneal). Our data indicate that ICI treatments significantly decreased the in vivo bioluminescence, indicating reduced tumor growth. Furthermore, anti-CTLA-4 and anti-PD-1 administration resulted in a significant long term anti-tumor activity, with ~90% and ~70% overall survival of anti-CTLA-4 and anti-PD-1 treated mice, respectively, while isotype control mice displayed ~10% survival by day 74 post-MB49-Luc cells inoculation. To investigate the potential development of systemic adaptive anti-tumor immunity elicited by ICI treatment, remaining ICI-treated mice and newly onboarded non-treated control mice have been (re)-challenged with MB49 tumor cells subcutaneously (s.c.). While all the control mice showed tumor outgrowth and needed to be sacrificed due to humane endpoint by the day 32 post-s.c. challenge, rechallenged ICI-treated mice showed potent abscopal effect and displayed no tumor engraftment with 100% overall survival. Altogether, these findings demonstrate that systemic ICI immunotherapies such as PD-1 and CTLA-4 elicit potent anti-tumor activity and induce protective anti-tumor immune memory. ICI might present an alternative or a complementary treatment to BCG therapy for NMIBC patients. Citation Format: Sulayman Benmerzoug, Katie Louche, Thibault Angles, Nizar Serhan, Frederique Dol-Gleizes, Pascale Lejeune, Sophie Chabot. Immune checkpoint therapy as a treatment option for non-muscle invasive bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2657.

A Comparative Analysis of Injectable vs. Intravesical Administration

Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity.

Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024

Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer

Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer

Abstract 2657: Immune checkpoint therapy as a treatment option for non-muscle invasive bladder cancer

Intravesical BCG therapy: implications for radiologists in abdominal imaging follow-up

Checkpoint Inhibition in Bladder Cancer: Clinical Expectations, Current Evidence, and Proposal of Future Strategies Based on a Tumor-Specific Immunobiological Approach

Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system

Intravesical Delivery Enhances Anti-Tumor Efficacy by Activating CD8+ T Cells with High CD69 and Low PD-1 Expression in Bladder Cancer.

Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database

Contemporary Treatment of NMIBC—Is It Time to Move on from BCG?

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs

Immune status for monitoring and treatment of bladder cancer

Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage

Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment

The Tumor Immune Profile of Bladder Cancer (BC) with HER2 Over-Expression and the Investigation into RC48-ADC Versus BCG in High-Risk Non-Muscle Invasive BC with HER2 Over-Expression.

Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

Developments in conservative treatment for BCG-unresponsive non-muscle invasive bladder cancer